Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation

Register of interests (PDF 294 KB)

Final draft guidance

Final draft guidance (PDF 242 KB)

Committee papers (PDF 1.52 MB)

Public committee slides (PDF 359 KB)

Equality impact assessment (PDF Version) (PDF 317 KB)

Draft guidance

Draft guidance (online commenting)

Draft guidance (PDF version) (PDF 285 KB)

Committee papers (PDF 6.68 MB)

Public committee slides (PDF 424 KB)

Equality impact assessment (PDF Version) (PDF 149 KB)

Committee meeting: 2

Register of Interests (PDF 295 KB)

Final scope (PDF 174 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 262 KB)

Equality impact assessment (Scoping) (PDF 131 KB)

Final stakeholder list (PDF 181 KB)

Draft scope post referral (PDF 183 KB)

Draft matrix post referral (PDF 174 KB)